

ICTRP Registry Profile

International Traditional Medicine Clinical Trial Registry (ITMCTR)





Basic Information

I.	Name of person completing this form	Taixiang Wu, Nannan SHI
II.	Role of the person completing this form (that is, the role of this person in the registry making this application)	Director, and Administrator
III.	Date this form was completed	29 /03 / _2022 dd
IV.	Signature of person completing this form	Shi Nannan
V.	Official Name of Registry (list abbreviation used, if relevant) Eg Australian and New Zealand Clinical Trials Registry (ANZCTR)	International Traditional Medicine Clinical Trial Registry (ITMCTR)
VI.	Registry postal address	16 Nanxiao Street, Dongzhimennei, Dongcheng District, Beijing, 100091, China
VII.	Registry street address (if different to postal address)	
VIII.	Registry URL (Registry's web site address)	http://itmctr.ccebtcm.org.cn/
IX.	Registration URL (Web site where users go to register a trial)	http://itmctr.ccebtcm.org.cn/UserPlatform/Login
X.	Application type	Application for Primary Registry status Application for Partner Registry status
XI.	What is the name of the agency (or agencies) that funds the registry?	China Academy of Chinese Medical Sciences; National Administration of Traditional Chinese Medicine; China Centre for Evidence Based Traditional Chinese Medicine
XII.	What is the name of the agency that manages the registry?	Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences





XIII.	Does the registry have an Advisory Board? *	Yes ⊠	No		
XIV.	If the registry has an Advisory Board, please describe its terms of reference, which organizations are represented on the Board, and how often it meets. If necessary, please attach this information to the application as a separate document.		c 2. Terms of Reference ory Group	of the I	TMCTR
XV.	Is registration of a clinical trial a legal requirement in the country (or countries) covered by the registry? *	Yes	No ⊠		
	If yes, please provide the title of the relevant law and information on how a copy of the law can be obtained (including the relevant web address)				
XVI.	Is registration of a clinical trial a requirement to obtain ethics approval in the country (or countries) covered by the registry? *	Yes In the	No SOP documents		
	If yes, please provide the title of the relevant document describing this requirement and information on how this document can be obtained (including the relevant web address)				
XVII.	Is the registry currently accepting clinical trials for registration?	Yes	No		
XVIII.	How many trials are on your da	tabase1	?		
On _27	_/_03_/_2022 there were _3426 d mm yyyy	_ trials	on the registry database.		
directly b	e ICTRP cannot consider a registry for P by Responsible Registrants. It is not acc vnloaded and imported from another regi	ceptable			
XIX.	Does the registry agree in princ International Standards for Clini			Yes ⊠	No





1. Content

1.1. The Registry will accept prospective registration of interventional clinical trials submitted by Responsible Registrants

1.1.1. Does the Registry register trials before the first participant has been recruited?	Yes	No
a) Does the Registry query submissions where registration is being sought after the first participant has been recruited?	Yes	No
b) Does the Registry make it clear to Responsible Registrants that prospective registration means that a trial must complete the registration process, <u>and</u> have a trial registration number issued, <u>before</u> the recruitment of the first participant.	Yes	No
1.1.2. Does the Registry register trials that have already recruited the first participant? (Also referred to as retrospective registration)	Yes	No
1.1.3. Does the Registry register other types of studies, including observational studies	Yes	No
1.1.4. Does the Registry register all trials submitted by Responsible Registrants	Yes	No
a) Does the Registry accept trials submitted by Responsible Registrants?	Yes	No
b) Does the Registry ask the person submitting a trial for registration to verify that they meet the terms and conditions for being a Responsible Registrant before being able to proceed to trial registration.	Yes 🖂	No
c) Does the Registry use the contact details provided by the Responsible Registrant to verify that those details are correct?	Yes	No
d) As a minimum, Registries must send an email to the address given and receive a reply from that same address. When possible, the telephone number and/or surface mail address will also be verified in a similar fashion.	Yes 🖂	No
e) Does the Registry ensure that all Responsible Registrants are associated with an institution or organization?	Yes	No
f) Does the Registry obtain institutional contact details for the Responsible Registrant, including name and telephone number of the institution?	Yes	No
1.1.5. Does the Registry accept studies for registration when the data is submitted as an electronic data file (eg as an xml file) Note: This is not a requirement and is being asked for information only.	Yes	No





1.2. The registry will be open to all prospective registrants (either internationally or within one or more specific countries) (ICMJE requirement)

a) Which types of study does the Registry accept for registration? (tick all ☐ Interventional studies ☐ Observational studies	that ap	ply)
b) If registration is restricted in some way (eg only accepts trials from sponsor, or in a particular health care condition (eg cancer) or intervised specify how it is restricted:		
Trials accepted for registration are those conducted in the field of t medicine from any country including Chinese medicine, acupunctu medicine, ayurvida, homeopathy, yonani, complementary and sup medicines.	ıre, he	erbal
c) From which countries does the Registry accept trials for registration:		
All countries over the world.		
1.3. The Registry will be able to collect and publicly display the WHO Trial Data Set (TRDS) (ICMJE requirement).	Regis	tration
a) Does the Registry collect and display, on a publicly accessible web site, all of the items in the WHO Trial Registration Data Set	Yes	No
b) Does the Registry have quality control procedures in place to ensure all items in the TRDS contain meaningful data?	Yes	No
 c) Does the Registry collect the optional TRDS data items? If yes, please specify: Contents in detail of the unique formular; Special outcomes and their test methods only belong to the traditional medicine. 	Yes	No
1.4. The Registry will make an effort to keep registered information up-to-o	date.	
a) Does the Registry permit Responsible Registrants to update information about their trial?	Yes	No
 b) Does the Registry have a reminder system to facilitate the submission of updated information by the Responsible Registrant. 	Yes	No
If yes, please state how often the Registry reminds Responsible Registrants to update their data (eg once every 6 months; once every year): Note: This is not a requirement and is being asked for information only.		
c) Does the Registry display the date the trial record was last updated? Note: This is not a requirement and is being asked for information only.	Yes	No
d) Does the Registry request updates from Responsible Registrants at least annually until the Registrant has recorded meaningful information about the publication of the trial results (e.g. has listed a citation in a "Publications" field)	Yes	No

Note: This is not a requirement and is being asked for information only.





1.5. Th	e Registry will <u>never</u> remove a trial once it has been registered.		
a)	Does the Registry ever delete a trial record from their database, or	Yes	No
	remove it from public view, once a registration number has been issued?		\boxtimes
	Issueu!		
If yes,	please explain the circumstances under which a record would be		
deletec			
b)	Does the Registry inform Responsible Registrants at the time of		
	registration that a trial cannot be deleted once it has been registered?	Yes	No
c)	Does the Registry have clear and transparent processes for dealing	Yes	No
	with requests to remove a trial record from public view, and have these processes been documented in the SOPs?	\boxtimes	
	these processes been documented in the SOF's:		
2 Qı	uality and Validity		
		ا مامام ا	: <u> </u>
	e Registry will have processes in place to make sure that registered ete and accurate.	ı data	IS
a)	Do Registry staff routinely check all data submitted about a trial for	Voc	No
α,	completeness and meaningfulness to ensure that all TRDS fields are	Yes	No
	populated and comply with the minimum standards?		
b)	5	Yes	No
	incomplete or not meaningful, do Registry staff contact the		
	Responsible Registrant and attempt to obtain complete and		
	meaningful data?		
c)	Does the Registry's database system apply automated checking procedures (e.g. range checks, logic rules) to data items to facilitate	Yes	No
	validity checking?	\boxtimes	
d)		Yes	No
,	register trials where the Responsible Registrant remains non-		
	compliant with requests to provide complete and meaningful data?		
e)	Does the Registry undertake regular internal quality control audits to	Yes	No
	assess the level of completeness and accuracy of the data collected?	\boxtimes	
	e Registry will have documented Standard Operating Procedures (S		
	will be aligned with the International Standards for Clinical Trial Reg		S
a)	Does the Registry have written standards for all procedures and	Yes	No
	processes employed by the registry? o These written standards are known as Standard Operating	\boxtimes	
	Procedures (SOPs)		
b)	Does the Registry use these SOPs to train all staff processing trial	Yes	No
,	registrations to ensure that common standards for ensuring data		
	completeness and meaningfulness are adhered to?		
c)	Are the internal registry-specific SOPs aligned with the WHO	Yes	No
	International Clinical Trial Registry Platform International Standards		П
1	for Clinical Trial Registration?		





2.3. The Registry will have processes in place to make sure that people and trials exist 2.3.1. Does the Registry make sure that the person registering the trial exists Yes No and that they are the appropriate Responsible Registrant? \boxtimes 2.3.2. Does the Registry make sure that the trial exists? Yes No \boxtimes If yes, please briefly describe what the registry does to make sure that the trial exists. We call or email the registrants for make sure that the trial exists. Does the Registry obtain written third-party confirmation that a trial Yes No exists? \boxtimes If yes, please specify the method of confirmation: An approval letter of IRB or ethics committee or/and an agency's support letter or issue number Does the Registry display in the trial record: No Yes a. if the registry has obtained written third party confirmation of \boxtimes the trial's existence, and b. the name of the third party from whom confirmation was received (eg the name of the ethics committee) 2.4. The Registry will have a publicly accessible audit trail so that changes made to the WHO TRDS for an individual trial can be tracked. Does the Registry allow Responsible Registrants to update their Yes No registered trial records? \boxtimes Does the Registry make available a publicly accessible audit trail of Yes No any changes to any TRDS items? \boxtimes Does the Registry have quality control procedures in place to ensure Yes No any updated information continues to fulfil the standards for each \boxtimes TRDS item? d) Does the Registry use the most up-to-date information as the default Yes No display? \bowtie e) Can the TRDS, as originally registered, be accessed at all times? Yes No \boxtimes 2.5. The Registry agrees to comply with the International Standards for Clinical Trial Registries (ISCTR). Does the Registry Administrator have a thorough working knowledge Yes Nο of the operational aspects of their registry? \boxtimes Is the Registry Administrator committed to ensuring that all Registry Yes No staff are familiar with the standards described in the ISCTR? \boxtimes Are all Registry staff familiar with the contents of the ISCTR? Yes No \boxtimes





3. Accessibility

o. Accessionity			
3.1. The Registry will make the <u>WHO TRDS</u> for all registered trials accessible to the public at no charge (ICMJE requirement).			
a) Does the Registry make the WHO TRDS items for all studies in their register (ie the registry database) accessible online at no charge to the end user?	Yes	No	
3.2. The Registry will make it possible for the <u>WHO TRDS</u> for all registered searched electronically (<i>ICMJE requirement</i>).	trials	to be	
a) Is it possible to search the Registry online using electronic searches of text words and phrases via a simple, single search box?	Yes	No	
b) Does the online search allow users to search in at least the condition field and the intervention field?	Yes	No	
c) When the results of a trial identified by a search are displayed, are all items in the WHO TRDS visible?	Yes	No	
d) Does the online search have an advanced search option? Note: This is not a requirement and is being asked for information only.	Yes	No	
3.3. The Registry will allow Responsible Registrants to submit a trial for reany time of day on any day of the week (24 hours a day, seven days a wee		ion at	
a) Is it possible to submit a trial to the registry 24 hours a day, seven (7) days a week?	Yes	No	
b) If the Registry is planning downtime, does it publish advance notice of downtime at least one (1) week beforehand?	Yes	No	
3.4. The Registry will allow their register database to be searched at any time of day on any day of the week (24 hours a day, seven days a week).			
a) Is it possible to search the register online 24 hours a day, 7 days a week?	Yes	No	





3.5. It is desirable that Registries in the WHO Registry Network also make the <a href="https://www.who.network.networ

,	Does the Registry accept and/or display trial information in languages others than English?	Yes ⊠	No
If yes, p Chinese	lease specify the languages used:		
Only ar	nswer the remaining questions in this section if the answer to the above qu	uestion	is <i>yes</i> .
	Does the Registry have quality control procedures in place to ensure that all translations are accurate?	Yes ⊠	No
c)	Are all TRDS items for all records also available in English?	Yes ⊠	No
·	Are all trial records translated into English by the Responsible Registrant checked by registry staff against the non-English submission before being accepted for registration?	Yes ⊠	No
,	Are all trial records translated by Registry staff checked by at least one other staff member?	Yes	No
,	If there is a discrepancy in a translation, is the translation checked by a third person?	Yes ⊠	No
	Does the Registry make users of the Registry aware of who performed the translation (the Responsible Registrant or Registry staff) of a registered record?	Yes ⊠	No
·	If a trial is registered in more than one language then will the Registry submit the "Scientific Title", and a language identifier, to the ICTRP Search Portal for each language used?	Yes	No ⊠





4. Unambiguous Identification

4.1.	The Registry will have in place processes to prevent the registration	n ot a	a single
trial ı	more than once on their database.		
а	Does the Registry make sure that a trial that has been submitted for	Voc	No

a)	Does the Registry make sure that a trial that has been submitted for	Yes	No
	registration is not already been included in their register by first searching and checking their own database?	\boxtimes	
b)	Does the Registry have policies and procedures in place to deal with inadvertent duplicate registration of the same trial within their own register?	Yes	No

4.2 The Registry will facilitate the retrospective linking (or bridging) on the WHO Search Portal of a single trial registered with more than one registry by entering <u>secondary identifiers</u>. This includes the <u>UTN</u>, and the unique identifiers allocated by other registries in the WHO Registry Network.

a)	Does the Registry require responsible Registrants to make an entry in the Secondary Identifiers field?	Yes	No
b)	If there are no known secondary identifiers, does the Registry require Responsible Registrants to enter 'Nil known' in the Secondary Identifiers field?	Yes ⊠	No
C)	Does the Registry require Responsible Registrants to enter a UTN? a. The UTN may be entered into either the Secondary Identifiers field or a field designated specifically for collection of the UTN is is not a requirement and is being asked for information only.	Yes	No

4.3. It is desirable that Primary Registries will search the ICTRP Search Portal and attempt to determine if the trial has already been registered by another Primary Registry in the WHO Registry Network or an ICMJE approved registry.

region y m me record region y record and reme approve a region y			
a) Does the Registry attempt to determine whether a submitted trial has been registered in another Primary Registry or an ICMJE approved registry before registration?	Yes	No	
Note: This is not a requirement and is being asked for information only.			





5. Technical Capacity				
5.1. The Registry will submit the <u>WHO TRDS</u> for <u>all</u> records on their register, in English, to the WHO ICTRP Central Repository.				
a) Will (or does) the Registry submit the WHO TRDS items for all records on their register, in English, to the WHO ICTRP Central Repository?	Yes	No		
 <u>Note</u>: If a registry accepts study types other than interventional trials (i.e. observational studies) these must be provided as well. 				
b) Will (or does) the Registry submit records in the format requested by the WHO ICTRP (e.g. xml file) at least once per month?	Yes	No		
c) Will (or does) the Registry, after the initial data transfer of all records, only submit new or updated records each time (rather than the entire data set every time)?	Yes	No		
5.2. The Registry will have access to a database that is used to store an submitted data.	d man	age the		
a) Does the Registry have access to a database that is used to store and manage the submitted data?	Yes	No		
b) Does the Registry use database software and hardware that guarantees reliable access to registered data and data safety at all times?	Yes	No		
5.3. The Registry will have access to adequate information technology s	upport	t.		
a) Does the Registry have access to reliable information technology support?	Yes	No		
b) Does the Registry have access to all of the following? a. reliable application, database, backup and mail servers b. good internet connectivity speed c. sound operating systems	Yes	No		
d. appropriate software for servers, desktops and laptops e. database and web development and maintenance personnel f. other skilled information technology personnel to support these systems, as required				
c) Please briefly describe the Registry's information technology infr separate document may be submitted separately if necessary)	astruct	ture. (A		
We have a professional IT team responsible for development of the system an the server.	d main	tenance		
5.4. The Registry will have adequate security and other provisions corruption and loss.	again	st data		
a) Does the Registry have documented procedures for ensuring adequate data security and other provisions to prevent data corruption and loss?	Yes	No		
b) Does the Registry issue alerts in advance of website downtime? If yes, please briefly describe how these alerts are circulated and who is responsible for circulating them.	Yes	No		
The monitor and our staff working 24 hours 7 days a week, so, we will know any abnormal of the website and will tell the IT team to solve the problem.				





6. Administration and Governance

within	ne Registry will have at least a national remit, and the support o the country (or region) to act as the Primary Registry for that cou ed as a group of countries and not a group of states within a country	ntry or		
	Does the Registry have at least a national remit?	Yes	No	
b)	Does the Registry have a letter of support, or other appropriate documentation, from the Ministry of Health or other relevant national or regional agencies?	Yes	No	
Note: Th	e letters of support must be submitted to the ICTRP Secretariat as part of the application			
China	From which country (or countries) does the Registry have the remit national (or regional) clinical trial registry?	to act	as the	
China				
d)	Registry:	suppo	rt to the	
Nation	al Administration of Traditional Chinese Medicine			
profit s		and	n ot-for-	
a)	Is the Registry managed by a not-for-profit agency?	Yes	No	
b)	Does the Registry publicly disclose its ownership, governance structures and not-for-profit status in a prominent place on the registry's website?	Yes	No	
c) www.co	What is the web address for the page where the ownership, governance and not-for-profit information is displayed? cebtcm.org.cn/portal/pageRegister?language=en_US#			
d)	Will the Registry inform the ICTRP immediately if their ownership, governance structures or not-for-profit status change in any way?	Yes	No	
(origin	ne Registry agrees that, should it cease to function, at least the al and updated) for all trial records will be transferred to a Primard Registry Network.			
a)	Will the Registry transfer at least the WHO TRDS (original and updated) for all trial records to another Primary Registry in the WHO Registry Network if it ceases to function?	Yes	No	
	6.4. The Registry will have a strategy in place ensure the medium to long term sustainability of the registry			
	Does the Registry have a documented business plan?	Yes	No	
b)	Does the Registry's business plan include strategies to ensure its medium to long term sustainability?	Yes	No	





7. The Trial Registration Data Set (TRDS)

7.1. The Registry will collect and publicly display all items in the WHO Trial Registration Data Set (TRDS)

	Item/Label	Does the registry collect this data item?	Does the registry publicly display this data item?
1	Primary Registry and Trial Identifying Number	Yes No ⊠ □	Yes No ⊠ □
2	Date of Registration in Primary Registry	Yes No ⊠ □	Yes No ⊠ □
3	Secondary Identifying Numbers	Yes No ⊠ □	Yes No ⊠ □
4	Source(s) of Monetary or Material Support	Yes No ⊠ □	Yes No ⊠ □
5	Primary Sponsor	Yes No ⊠ □	Yes No ⊠ □
6	Secondary Sponsor(s)	Yes No ⊠ □	Yes No ⊠ □
7	Contact for public queries	Yes No ⊠ □	Yes No ⊠ □
8	Contact for scientific queries	Yes No ⊠ □	Yes No ⊠ □
9	Public title	Yes No ⊠ □	Yes No ⊠ □
10	Scientific title	Yes No ⊠ □	Yes No ⊠ □
11	Countries of Recruitment	Yes No ⊠ □	Yes No ⊠ □
12	Health condition(s) or problem(s) studied	Yes No ⊠ □	Yes No ⊠ □
13	Interventions	Yes No ⊠ □	Yes No ⊠ □
14	Key Inclusion and Exclusion Criteria	Yes No ⊠ □	Yes No ⊠ □
15	Study type	Yes No ⊠ □	Yes No ⊠ □
16	Date of first enrolment	Yes No ⊠ □	Yes No ⊠ □
17	Sample size	Yes No ⊠ □	Yes No ⊠ □
18	Recruitment status	Yes No ⊠ □	Yes No ⊠ □
19	Primary Outcome(s)	Yes No ⊠ □	Yes No ⊠ □
20	Key Secondary Outcome(s)	Yes No ⊠ □	Yes No ⊠ □
21	Ethics Review	Yes No ⊠ □	Yes No ⊠ □





	Item/Label	Does the registry collect this data item?	Does the registry publicly display this data item?
22	Completion date	Yes No ⊠ □	Yes No ⊠ □
23	Summary Results	Yes No ⊠ □	Yes No ⊠ □
24	IPD sharing statement	Yes No ⊠ □	Yes No ⊠ □

7.2. The Registry may choose to collect and publicly display other data items. It is recommended that registries consider the following optional, additional data items:

Item/Label	Does the registry collect this data item?	Does the registry publicly display this data item?
Lay Summary / Synopsis	Yes No ⊠ □	Yes No ⊠ □
Approvals	Yes No ⊠ □	Yes No ⊠ □
Results links	Yes No ⊠ □	Yes No ⊠ □

URL	Yes No	Yes No





8. Partner Registries

	imary Registries in the WHO Registry Network will have the capac ther Registries.	ity to	partner
a)	Registries that do not themselves fulfil the criteria for a Primary Registry in the WHO Registry Network?	Yes	No
b) If yes, p	Does the Registry currently have any Partner Registries? please provide the name(s) of these partners:	Yes	No ⊠
c)	Registry's web site?	Yes	No
Note: A	completed Registry Profile form is required for all Partner Registries. This profile will be		
	imary Registries in the WHO Registry Network will ensure that poteries meet WHO minimum standards requirements.	ntial Pa	artner
a)	accept a Partner Registry and their trial registration records, they will make sure that the Partner Registry meets all the WHO minimum standards listed in the International Standards for Clinical Trial Registries?	Yes	No
b)	Has a Registry Profile form been completed and submitted for all of the Registry's Partner Registries?	Yes	No
	imary Registries will have procedures in place to enable exchange or Registries.	of data	with
a)	Is the Registry able to accept data (that is, as electronic data files) from Partner Registries or other appropriate data providers?	Yes	No
b)	Does the Registry agree to establish a Memorandum Of Understanding (MOU) or other such agreement with each Partner Registry or other data providers, as per the requirement described in the International Standards for Clinical Trial Registries?	Yes	No
c)	Does the Primary Registry agree the area of coverage/responsibility of their Partner Registries or other data providers (such as geographical location, health condition, intervention type, etc) and incorporate this into their SOPs and instructions to Registrants to avoid any confusion or unintentional duplicate registration?	Yes	No
d)	Does the Primary Registry record the identification number and date of registration in the Partner Registry within the trial record on the Primary Registry?	Yes	No
e)	Does the Primary Registry identify records that have been sourced from Partner Registries or other data providers so users are aware of the data source?	Yes	No
f)	Before announcing Partner Registries, Primary Registries must have successfully imported data into the Primary Registry?	Yes	No

 \boxtimes





Contact Information

Administrator

The Administrator is the person employed to manage the Registry and will be the primary point of contact between the Registry and the ICTRP Secretariat.

Title (Dr/Prof/Mr/Mrs/Ms/Miss)	Prof.
Given Name	Taixiang
Family Name	WU
Telephone number	+86 18980604562
Fax	
Email	Chictr001@chictr.org.cn

Title (Dr/Prof/Mr/Mrs/Ms/Miss)	Prof.
Given Name	Nannan
Family Name	SHI
Telephone number	+86 13811839164
Fax	+86 10 84032881
Email	13811839164@vip.126.com

Secondary Contact

The Secondary Contact must not be the same as the Administrator. Secondary contact details are requested for circumstances when the Administrator is unavailable.

Title (Dr/Prof/Mr/Mrs/Ms/Miss)	Dr.
Given Name	Chen
Family Name	ZHAO
Telephone number	+86 15611290766
Fax	+86 10 84032881
Email	Zyyzc2007@163.com

Information Technology Officer

The Information Technology Officer should be the person who will be responsible for submitting the data for inclusion on the ICTRP Central Repository. They should have a good understanding of all of the IT issues relevant to the registry.

Title (Dr/Prof/Mr/Mrs/Ms/Miss)	Mr.
Given Name	Yufeng





Family Name	GAN
Telephone number	+86 18519232345
Fax	
Email	<u>18519232345@163.com</u>